# FDA approves MSD’s Lipfendra as first oral PCSK9 inhibitor - European Pharmaceutical Review

*Источник: European Pharmaceutical Review*
*Дата: 2026-07-21*
*Язык: en*

<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxNdENObW1GaTJseldJU1YxazR4aDBGV3E1SFc5QWY2a3R6MVp5RFV4MUxraXg5VmhDbEtZdzRoRThqUzFrNUZ5V3BQZjdBZVBKMDZ0ZWl5ZG1yVFgxeW5tYzFLVTRwVEEySjBYSktjSWRtSnpIeHM4MFJ0LTBwR0YyaTd6TV9FVWs2RVJnMHhQT1Q1MnZPc0dsd05PTGY4eXVOMzQzY1ZLTkFqdkFaVEszZWlUZVF6d2J6M1E?oc=5" target="_blank">FDA approves MSD’s Lipfendra as first oral PCSK9 inhibitor</a>&nbsp;&nbsp;<font color="#6f6f6f">European Pharmaceutical Review</font>

[Оригинал](https://news.google.com/rss/articles/CBMiugFBVV95cUxNdENObW1GaTJseldJU1YxazR4aDBGV3E1SFc5QWY2a3R6MVp5RFV4MUxraXg5VmhDbEtZdzRoRThqUzFrNUZ5V3BQZjdBZVBKMDZ0ZWl5ZG1yVFgxeW5tYzFLVTRwVEEySjBYSktjSWRtSnpIeHM4MFJ0LTBwR0YyaTd6TV9FVWs2RVJnMHhQT1Q1MnZPc0dsd05PTGY4eXVOMzQzY1ZLTkFqdkFaVEszZWlUZVF6d2J6M1E?oc=5&ucbcb=1&hl=en-US&gl=US&ceid=US:en)